General discussion, page-11697

A review of clinical trial literature in psychedelics treatment published a few years ago came up with these consistent conclusions. In all studies, psychedelic drugs were administered in combination with psychological treatment.

It is a long essay but here is the gist:

The key findings from the studies in this literature review support the idea that one or a few doses of a classic psychedelic drug, most commonly psilocybin, have immediate and sustained efficacy in multiple mental disorders. None of the nine studies reported serious adverse effects. The two largest randomised controlled trials independently reached the same conclusion, namely that psilocybin has significant and lasting efficacy against cancer-related anxiety and depression. Altogether the studies show that psilocybin and LSD are efficacious against anxiety and depression in cases of life-threatening illness.

If the existing results can be confirmed in future studies, the immediate and sustained efficacy of a single dose will introduce a new principle in psychiatric treatment.

Current antidepressant drugs only begin to work after a few weeks and must be taken daily. A treatment effect with more rapid onset would be advantageous. Sustained efficacy of a single dose would also be beneficial compared to the daily administration of drugs and the associated adverse effects. Furthermore, psychedelic drugs have a different mechanism of action to currently available antidepressants, namely 5-HT2A agonism as opposed to predominantly monoamine reuptake inhibition.

https://tidsskriftet.no/en/2018/11/oversiktsartikkel/psychedelic-drugs-treatment-anxiety-depression-and-addiction

I think the clear message time and time again is that the probability of clinical trial success for IHL is highly favorable across all of its suite. There is a lot of great research that has been posted on HC so I won't regurgitate but it is overwhelming.

It is a great time to stay focused, things turn quickly - look at Mindmed overnight. Looking at literature on adverse effects, it certainly appears that Psilocybin has an edge over LSD.